For a patient with non-small cell lung cancer (NSCLC) harboring an EGFR or ALK mutation that transforms into small cell lung cancer (SCLC), would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?